Blog

Deadline for Completion of Actos Settlement Approaching

All Actos bladder cancer cases that were part of the Multi-District Litigation (“MDL”) involving use of Actos prior to Dec. 1, 2011, and most other Actos cases filed elsewhere,  were settled as of April 28, 2015.  This includes all Actos clients who had retained Locks Law Firm to represent them as of that date.  The settlement includes nearly 9,000 cases for a total of $2.4 billion.  Completed claims packages with all required supporting documentation must be submitted by January 8, 2016.  The Locks Law Firm pharmaceutical team has been working diligently to meet this deadline and ensure that all of our Actos clients receive the highest possible offers.  It is not known how long it will take for all of the cases to be processed and paid, but we are hopeful that everything will be concluded in 2016.  Locks Law Firm continues to accept Actos cases for persons who used Actos prior to Dec. 1, 2011 and were diagnosed with bladder cancer within the last two years.

Tell Us About Your Case

If you can read this, please avoid filling the following input field or your submission may be marked as spam.
Thank you for contacting us! We will be in touch with you shortly.

Recent Entries

Archive

Locks Law Firm only provides legal advice after having entered into an attorney client relationship, which our website specifically does not create. Conversations that originate from website messaging, chat or other two way web based engagement  do not create an attorney client relationship. It is imperative that any action taken be done on the advice of counsel. Because every case is different, the description of awards and cases previously handled do not guarantee a similar outcome in current or future cases. The firm practices law in Pennsylvania, New Jersey & New York as Locks Law Firm. Super Lawyers, Best Lawyers in America and other organizations that rate attorneys are not designations that have been approved by the State Supreme Courts or the American Bar Association.